Abstract
Several studies have shown the benefit of fluorine-18 fluorodeoxy glucose (FDG) imaging in the differentiation of solitary pulmonary nodules. The majority of malignant tumor have a higher glucose metabolic rate as compared to benign lesions. However, there is a considerable variety in glucose metabolic rate that depends on the aggressiveness and histological subtype of the tumor. Technetium-99m sestamibi (MIBI) is another tumor imaging agent for SPECT. We present a case of bronchioloalveolar cell carcinoma with a false negative finding in FDG imaging and a positive finding in MIBI imaging. This case clearly indicates that the FDG uptake and MIBI uptake might provide different information regarding characteristics of lung cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 499-501 |
| Number of pages | 3 |
| Journal | Annals of nuclear medicine |
| Volume | 17 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Sep 2003 |
| Externally published | Yes |
Fingerprint
Keywords
- Bronchioloalveolar cell carcinoma
- Fluorine-18 fluorodeoxy glucose
- Lung cancer
- Myocardial perfusion SPECT
- Technetium-99m sestamibi
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Cite this
Discrepant uptake between fluorine-18 fluorodeoxy glucose and Tc-99m sestamibi in bronchioloalveolar cell carcinoma. / Higuchi, Takahiro; Tagawa, Syoutoku; Yoshida, Naohiro; Araki, Tsutomu; Tsuchiya, Taketsugu; Higashi, Koutarou; Taki, Junichi; Kinuya, Seigo; Nakajima, Kenichi; Ikeda, Masatoshi; Namura, Masanobu; Tonami, Norihisa.
In: Annals of nuclear medicine, Vol. 17, No. 6, 09.2003, p. 499-501.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Discrepant uptake between fluorine-18 fluorodeoxy glucose and Tc-99m sestamibi in bronchioloalveolar cell carcinoma
AU - Higuchi, Takahiro
AU - Tagawa, Syoutoku
AU - Yoshida, Naohiro
AU - Araki, Tsutomu
AU - Tsuchiya, Taketsugu
AU - Higashi, Koutarou
AU - Taki, Junichi
AU - Kinuya, Seigo
AU - Nakajima, Kenichi
AU - Ikeda, Masatoshi
AU - Namura, Masanobu
AU - Tonami, Norihisa
PY - 2003/9
Y1 - 2003/9
N2 - Several studies have shown the benefit of fluorine-18 fluorodeoxy glucose (FDG) imaging in the differentiation of solitary pulmonary nodules. The majority of malignant tumor have a higher glucose metabolic rate as compared to benign lesions. However, there is a considerable variety in glucose metabolic rate that depends on the aggressiveness and histological subtype of the tumor. Technetium-99m sestamibi (MIBI) is another tumor imaging agent for SPECT. We present a case of bronchioloalveolar cell carcinoma with a false negative finding in FDG imaging and a positive finding in MIBI imaging. This case clearly indicates that the FDG uptake and MIBI uptake might provide different information regarding characteristics of lung cancer.
AB - Several studies have shown the benefit of fluorine-18 fluorodeoxy glucose (FDG) imaging in the differentiation of solitary pulmonary nodules. The majority of malignant tumor have a higher glucose metabolic rate as compared to benign lesions. However, there is a considerable variety in glucose metabolic rate that depends on the aggressiveness and histological subtype of the tumor. Technetium-99m sestamibi (MIBI) is another tumor imaging agent for SPECT. We present a case of bronchioloalveolar cell carcinoma with a false negative finding in FDG imaging and a positive finding in MIBI imaging. This case clearly indicates that the FDG uptake and MIBI uptake might provide different information regarding characteristics of lung cancer.
KW - Bronchioloalveolar cell carcinoma
KW - Fluorine-18 fluorodeoxy glucose
KW - Lung cancer
KW - Myocardial perfusion SPECT
KW - Technetium-99m sestamibi
UR - http://www.scopus.com/inward/record.url?scp=12444342657&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=12444342657&partnerID=8YFLogxK
U2 - 10.1007/BF03006442
DO - 10.1007/BF03006442
M3 - Article
C2 - 14575387
AN - SCOPUS:12444342657
VL - 17
SP - 499
EP - 501
JO - Annals of Nuclear Medicine
JF - Annals of Nuclear Medicine
SN - 0914-7187
IS - 6
ER -